Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).

NCT07020377 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus
Non Alcholic Fatty Liver Disease

Interventions

DRUG: Dapagliflozin (DAPA)
DRUG: Placebo
OTHER: Negative control

Sponsor

Amira Bisher,PhD

Collaborators

[object Object]
[object Object]